Visanji J M, Seargent J, Tahri D, Croft S A, Makris M, Preston F E, Peake I R, Daly M E
Division of Molecular and Genetic Medicine, University of Sheffield Faculty of Medicine, Royal Hallamshire Hospital, Sheffield, UK.
Br J Haematol. 2000 Jul;110(1):135-8. doi: 10.1046/j.1365-2141.2000.02152.x.
Elevated plasminogen activator inhibitor 1 (PAI-1) levels are associated with venous thromboembolism, although their significance is unclear. PAI-1 levels are influenced by a PAI-1 promoter dimorphism (4G/5G), the 4G allele being associated with increased PAI-1 activity. We investigated whether the 4G allele influenced thrombotic risk by studying 99 symptomatic factor V (FV) Leiden heterozygotes and 99 healthy subjects. The 4G allele was more prevalent among cases than among healthy subjects (chi2 = 8.00, P = 0.005) and the odds ratio (OR) for thrombosis associated with either heterozygosity or homozygosity for the 4G allele was 2.43 (P = 0. 011). We conclude that carriership of the 4G allele was more prevalent in patients who already carried factor V Leiden than in control subjects without factor V Leiden.
纤溶酶原激活物抑制剂1（PAI-1）水平升高与静脉血栓栓塞有关，但其意义尚不清楚。PAI-1水平受PAI-1启动子二态性（4G/5G）影响，4G等位基因与PAI-1活性增加有关。我们通过研究99例有症状的因子V（FV）Leiden杂合子和99例健康受试者，调查4G等位基因是否影响血栓形成风险。4G等位基因在病例中比在健康受试者中更普遍（χ2 = 8.00，P = 0.005），与4G等位基因杂合或纯合相关的血栓形成优势比（OR）为2.43（P = 0.011）。我们得出结论，4G等位基因携带者在已携带因子V Leiden的患者中比在没有因子V Leiden的对照受试者中更普遍。
Zotero 插件